Researchers create stem cell model to identify potential targeted epilepsy treatment
In a new study published in the scientific journal Brain, researchers at Children’s Hospital of Philadelphia have used…
Extra bolagsstämma
Aktieägarna i Fluicell AB (publ), org.nr 556889-3282, kallas härmed till extra bolagsstämma torsdagen den 4 januari 2024 kl….
30
Nov
2023
Fluicell publishes 2023 Q3 Interim report
Today, August 2023, Fluicell publishes the financial report for the period January 1 to June 30, 2023. The…
30
Nov
2023
Fluicell at ATMP Sweden 2023
Building a strong community that contains therapeutic developers, healthcare organizations, and infrastructure and service providers is essential for…
27
Nov
2023
The shape of medicine to come – Presentation with CEO Carolina Trkulja
Did you miss the presentation last week by CEO Carolina Trkulja on how Fluicell is transforming how we…
09
Nov
2023
Fluicell CEO Newsletter 03, 2023
“I see great potential in our technology, and I think we have only scratched the surface of what…
26
Oct
2023
A Fluicell ready to address future health challenges
Over the past year, Fluicell has made significant progress in the development of bioprinted tissue-based products for therapeutic…
24
Oct
2023
Non-animal research models workshop
Tomorrow, we have the honor of hosting a workshop on non-animal models in research and drug development, featuring…
17
Oct
2023
Bioprinted cancer models using de-cellularized tumors
Faithfully replicating the tumor microenvironment is critical for understanding cancer development. In our new application note In our…
02
Oct
2023